Cargando…
PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors
Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the therapeutic management of advanced non-small cell lung cancer (aNSCLC) over the last decade. However, there is an unmet need for clinically useful biomarkers in this patient subgroup. The aim of this study was to combine baseline...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280986/ https://www.ncbi.nlm.nih.gov/pubmed/32429368 http://dx.doi.org/10.3390/cancers12051257 |
_version_ | 1783543826029215744 |
---|---|
author | Dimitrakopoulos, Foteinos-Ioannis Nikolakopoulos, Achilleas Kottorou, Anastasia Kalofonou, Fotini Liolis, Elias Frantzi, Theodora Pyrousis, Ioannis Koutras, Angelos Makatsoris, Thomas Kalofonos, Haralabos |
author_facet | Dimitrakopoulos, Foteinos-Ioannis Nikolakopoulos, Achilleas Kottorou, Anastasia Kalofonou, Fotini Liolis, Elias Frantzi, Theodora Pyrousis, Ioannis Koutras, Angelos Makatsoris, Thomas Kalofonos, Haralabos |
author_sort | Dimitrakopoulos, Foteinos-Ioannis |
collection | PubMed |
description | Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the therapeutic management of advanced non-small cell lung cancer (aNSCLC) over the last decade. However, there is an unmet need for clinically useful biomarkers in this patient subgroup. The aim of this study was to combine baseline clinical characteristics of aNSCLC patients, in the form of a scoring system, and to investigate its predictive and prognostic value in NSCLC patients treated with ICIs. A total of 112 patients with advanced (stages IIIA to IV) NSCLC, treated with nivolumab or pembrolizumab, were enrolled in this study. Patras Immunotherapy Score (PIOS) was developed based on four of the studied parameters (performance status (PS), body mass index (BMI), age, and lines of treatment (LOT), which were incorporated into our formula (PS × BMI/ LOT × age). PIOS score was strongly associated with best overall responses (BOR), with those patients having benefit/good response (stable disease (SD) or partial (PR) or complete response (CR), achieving a higher score compared to patients who developed progressive disease (PD) (p < 0.001). Furthermore, PIOS score was associated with progression-free survival (PFS), since high-score patients had longer PFS (p < 0.001, hazard ratio (HR) = 0.469). Moreover, PIOS was associated with post-immunotherapy overall survival (OS), with high-score patients having improved OS (log-rank p = 0.019). This study suggests that a combination of baseline parameters, which give rise to PIOS score, may predict the best response of NSCLC patients treated with anti-program cell death -1 (PD-1) monotherapy as well as it may have a potent prognostic value for PFS and post immunotherapy OS. |
format | Online Article Text |
id | pubmed-7280986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72809862020-06-15 PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors Dimitrakopoulos, Foteinos-Ioannis Nikolakopoulos, Achilleas Kottorou, Anastasia Kalofonou, Fotini Liolis, Elias Frantzi, Theodora Pyrousis, Ioannis Koutras, Angelos Makatsoris, Thomas Kalofonos, Haralabos Cancers (Basel) Article Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the therapeutic management of advanced non-small cell lung cancer (aNSCLC) over the last decade. However, there is an unmet need for clinically useful biomarkers in this patient subgroup. The aim of this study was to combine baseline clinical characteristics of aNSCLC patients, in the form of a scoring system, and to investigate its predictive and prognostic value in NSCLC patients treated with ICIs. A total of 112 patients with advanced (stages IIIA to IV) NSCLC, treated with nivolumab or pembrolizumab, were enrolled in this study. Patras Immunotherapy Score (PIOS) was developed based on four of the studied parameters (performance status (PS), body mass index (BMI), age, and lines of treatment (LOT), which were incorporated into our formula (PS × BMI/ LOT × age). PIOS score was strongly associated with best overall responses (BOR), with those patients having benefit/good response (stable disease (SD) or partial (PR) or complete response (CR), achieving a higher score compared to patients who developed progressive disease (PD) (p < 0.001). Furthermore, PIOS score was associated with progression-free survival (PFS), since high-score patients had longer PFS (p < 0.001, hazard ratio (HR) = 0.469). Moreover, PIOS was associated with post-immunotherapy overall survival (OS), with high-score patients having improved OS (log-rank p = 0.019). This study suggests that a combination of baseline parameters, which give rise to PIOS score, may predict the best response of NSCLC patients treated with anti-program cell death -1 (PD-1) monotherapy as well as it may have a potent prognostic value for PFS and post immunotherapy OS. MDPI 2020-05-16 /pmc/articles/PMC7280986/ /pubmed/32429368 http://dx.doi.org/10.3390/cancers12051257 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Dimitrakopoulos, Foteinos-Ioannis Nikolakopoulos, Achilleas Kottorou, Anastasia Kalofonou, Fotini Liolis, Elias Frantzi, Theodora Pyrousis, Ioannis Koutras, Angelos Makatsoris, Thomas Kalofonos, Haralabos PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors |
title | PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors |
title_full | PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors |
title_fullStr | PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors |
title_full_unstemmed | PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors |
title_short | PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors |
title_sort | pios (patras immunotherapy score) score is associated with best overall response, progression-free survival, and post-immunotherapy overall survival in patients with advanced non-small-cell lung cancer (nsclc) treated with anti-program cell death-1 (pd-1) inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280986/ https://www.ncbi.nlm.nih.gov/pubmed/32429368 http://dx.doi.org/10.3390/cancers12051257 |
work_keys_str_mv | AT dimitrakopoulosfoteinosioannis piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors AT nikolakopoulosachilleas piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors AT kottorouanastasia piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors AT kalofonoufotini piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors AT lioliselias piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors AT frantzitheodora piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors AT pyrousisioannis piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors AT koutrasangelos piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors AT makatsoristhomas piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors AT kalofonosharalabos piospatrasimmunotherapyscorescoreisassociatedwithbestoverallresponseprogressionfreesurvivalandpostimmunotherapyoverallsurvivalinpatientswithadvancednonsmallcelllungcancernsclctreatedwithantiprogramcelldeath1pd1inhibitors |